Captopril NDC 73190-026

NDC codes

FDA NDC Directory

Product NDC (as listed)73190-026Labeler and product segments. Claims need a package NDC.

Product NDC at billing width73190-0026Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
73190-026-01	73190002601	100 TABLET in 1 BOTTLE (73190-026-01)Marketed from Apr 22, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Captopril
Generic name (nonproprietary): captopril
Active ingredients: Captopril — 12.5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: AvKARE
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 074737
Marketing start: Apr 22, 2025
Listing expires: Dec 31, 2026
Other FDA classes: Angiotensin-converting Enzyme Inhibitors (Mechanism)
Identifiers: Product ID 73190-026_3362ca7d-8142-bdbc-e063-6394a90acb77SPL ID 3362ca7d-8142-bdbc-e063-6394a90acb77SPL set ID 3362b7a8-026a-b277-e063-6394a90a9dc6RxCUI 308963, 308964, 317173UNII 9G64RSX1XDUPC 0373190028018, 0373190027011, 0373190026014
Pharmacologic class: Angiotensin Converting Enzyme Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N473190002601 followed by a unit qualifier and the quantity

Package 73190-0026-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 22, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE Hypertension: Captopril tablets, USP are indicated for the treatment of hypertension. In using captopril, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril is effective alone and in combination with other antihypertensive agents, especiall…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 074737

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 074737
Product	Strength	Form · route	Labeler	Product NDC
Captopril	Captopril 25 mg/1	TabletOral	Camber Pharmaceuticals, Inc.	31722-142
Captopril	Captopril 12.5 mg/1	TabletOral	Camber Pharmaceuticals, Inc.	31722-141
Captopril	Captopril 50 mg/1	TabletOral	Camber Pharmaceuticals, Inc.	31722-143
Captopril	Captopril 100 mg/1	TabletOral	Camber Pharmaceuticals, Inc.	31722-144
Captopril	Captopril 25 mg/1	TabletOral	AvKARE	73190-027
Captopril	Captopril 50 mg/1	TabletOral	AvKARE	73190-028